Translate Bio, Inc. Overview
Pro stress-test →Translate Bio is a clinical-stage mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction. Once a public NASDAQ-listed company (TBIO), it was acquired by Sanofi in September 2021 for $3.2 billion and now operates as a wholly-owned subsidiary within Sanofi's mRNA Center of Excellence.
Strategic Profile
Pro stress-test →The company leverages over 10 years of mRNA research and development expertise to develop therapeutic candidates and vaccines in collaboration with Sanofi's vaccine and drug development capabilities. Its platform targets multiple therapeutic areas including infectious diseases, rare genetic disorders, and oncology, positioning it as a core pillar of Sanofi's mRNA innovation strategy.
Competitive Landscape
Pro stress-test →Within the mRNA therapeutics space, Translate Bio competes with other mRNA platform companies and vaccine developers. Key competitors include Moderna, BioNTech, and other mRNA-focused biotechs. However, as a Sanofi subsidiary, Translate Bio now benefits from Sanofi's broader competitive positioning in vaccines, immunology, oncology, and rare diseases, with synergies across these therapeutic areas.
Industry Context
Translate Bio, Inc. operates in mRNA therapeutics and vaccines.
Key facts
Founded: 2011 · Headquarters: Lexington, MA, USA · Employees: 201-500 · Revenue: N/A (subsidiary) · Market cap: N/A (subsidiary)